In the inhibition of RAS‐related pathway, it is showed that cotreatment with trametinib and osimertinib resensitizes the EGFR mutant NSCLC cell line with KRASG12V to osimertinib.270. Here, EGFR is linked to non-small cell lung carcinoma.